1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Senti Bio Raises $105m Series B Round For CAR-NKs, Led By Leaps For Bayer

Company Anticipates IND Filing In 2022-2023

 
• By Alaric DeArment

The investment is the latest in Bayer’s series of moves into cell and gene therapy, amid growing industry interest in CAR-NKs.

3d illustration of immune system T cells attacking cancer cells (CAR T-cell therapy) - Illustration
Senti Bio raises $105m in Series B round to develop chimeric antigen receptor natural killer cell therapies. • Source: Shutterstock

Bayer AG’s venture capital arm has leapt into another cell and gene therapy financing deal, ushering in the new year with a continuation of a string of investments in the space by the VC division and the company itself that has been going at a fast clip during the past year. Meanwhile, Senti Biosciences, the start-up it is investing in, plans to use the funding to support preclinical development of its next-generation natural killer cell-based chimeric antigen receptor therapy (CAR-NK) therapies.

Leaps by Bayer and Senti Biosciences announced 6 January that the former had led a $105m series B round in South San Francisco, California-based Senti, with participation by Matrix Partners China, Mirae Asset Capital, Ridgeback Capital and Intel Capital

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.

In Brief: Strong OS Results For Immutep’s Eftilagimod/Keytruda Combo In Head And Neck Cancer

 
• By Sushmita Panda

Australian firm's combo of eftilagimod and Keytruda shows 17.6-month median overall survival in first-line HNSCC patients with low PD-L1, raising hopes for potential accelerated approval.

In Brief: Positive New Data For Aptose’s Triplet Therapy In 1L AML

 
• By Sushmita Panda

Aptose’s tuspetinib triplet shows early mutation-agnostic promise in new data from Phase I/II program for frontline acute myeloid leukemia.

BioNTech Aims To Diversify BNT323 Manufacturing As Filing Nears

 
• By Alaric DeArment

The company plans to expand manufacturing of the HER2-targeting ADC beyond China and plans to file for US FDA approval in 2025.

More from Therapy Areas

In Brief: Positive New Data For Aptose’s Triplet Therapy In 1L AML

 
• By Sushmita Panda

Aptose’s tuspetinib triplet shows early mutation-agnostic promise in new data from Phase I/II program for frontline acute myeloid leukemia.

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By Xu Hu

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.

Aldeyra Plans To File Reproxalap Again With New Dry Eye Symptom Data

 
• By Joseph Haas

The biotech hopes a third time will be the charm after two FDA complete responses, with plans to position its eye drop as offering quicker onset of action.